TITLE

Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study

AUTHOR(S)
Nolte, Thomas; Schutter, Ulf; Loewenstein, Oliver
PUB. DATE
January 2014
SOURCE
Pragmatic & Observational Research;2014, Vol. 5, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Strong opioids, including oxycodone, are the most effective analgesics used to combat moderate to severe cancer pain, but opioid-induced bowel dysfunction is a relevant problem associated with the therapy. Clinical studies have demonstrated equivalent analgesic efficacy and improved bowel function in treatment with a fixed combination of prolonged-release (PR) oxycodone and PR naloxone compared to oxycodone alone in patients with nonmalignant pain. Here, we report of a prospective, non-interventional study evaluating the effectiveness and safety of PR oxycodone/PR naloxone in a subgroup of patients with severe cancer pain. Patients and methods: Within the non-interventional multicenter study, 1,178 cancer patients with severe chronic pain received PR oxycodone/PR naloxone, dosed according to pain intensity, for 4 weeks. Recorded variables included pain intensity, patient-reported bowel function (Bowel Function Index), and pain-related functional impairment as a measure of quality of life (QoL). Results: During treatment with PR oxycodone/PR naloxone, clinically relevant improvements in pain intensity were observed in opioid-naïve patients and in patients pretreated with weak or strong opioids, as reflected by reductions in pain scores of 51%, 53%, and 33%, respectively. Improvement in analgesia was paralleled by a significant reduction of opioid-induced bowel dysfunction in opioid-pretreated patients. The reductions in the mean Bowel Function Index of -20.5 and -36.5 in patients pretreated with weak and strong opioids, respectively, represent clinically relevant improvements in bowel function. Pain-related functional impairment decreased consistently across all seven domains, which is equivalent to a substantial improvement in QoL. Conclusion: This subgroup analysis of cancer patients within a large non-interventional study demonstrates that treatment with PR oxycodone/PR naloxone provides effective analgesia with minimization of bowel dysfunction and improved QoL. These data extend our knowledge of the effectiveness and tolerability of PR oxycodone/PR naloxone to the population of patients with cancer under real-life conditions.
ACCESSION #
94751975

 

Related Articles

  • The place of oxycodone/naloxone in chronic pain management. Leppert, Wojciech // Contemporary Oncology / Wspolczesna Onkologia;2013, Vol. 17 Issue 2, p128 

    Opioid analgesics are usually effective in the management of severe chronic pain. However, symptoms of opioid-induced bowel dysfunction (OIBD) are common during opioid therapy. Opioid-induced bowel dysfunction is often unsuccessfully managed due to limited effectiveness and numerous adverse...

  • Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. Madeo, Graziella; Schirinzi, Tommaso; Natoli, Silvia; Pierantozzi, Mariangela; Stefani, Alessandro; Dauri, Mario; Pisani, Antonio // Journal of Neurology;Sep2015, Vol. 262 Issue 9, p2164 

    Pain is a relevant and often underestimated non-motor symptom affecting the quality of life of patients with Parkinson's disease (PD). Although some pain symptoms can be effectively treated by dopaminergic medication, a correct diagnosis of the different types and distribution of pain in PD is...

  • Pharmacological approach to chronic visceral pain. Focus on oxycodone controlled release: an open multicentric study. LIGUORI, S.; GOTTARDI, M.; MICHELETTO, G.; BRUNO, L. // European Review for Medical & Pharmacological Sciences;2010, Vol. 14 Issue 3, p185 

    Background and Objectives: Visceral pain is a significant issue for patients, and the importance of treating pain is underestimated. New opioid formulations, the primary treatment option for moderate-to-severe pain, have been shown to be effective, but no studies have been conducted to address...

  • Oxycodone/naloxone withdrawal.  // Reactions Weekly;Sep2015, Vol. 1569 Issue 1, p162 

    The article presents a case study of a female patient with a history ofend-stage liver failure who developed various toxicities after a single dose administration of oxycodone/naloxone.

  • a quick look. Dunkin, Mary Anne // Arthritis Today;Jul/Aug2010, Vol. 24 Issue 4, p63 

    The article offers information on the analgesics, a type of pain relieving medication. Acetaminophen is a non-opioid analgesic available over the counter and by prescription, while opioid analgesics require a prescription. The article provides a chart listing analgesics such as morphine sulfate,...

  • Is there enough evidence to advocate opioid combinations? Does one and one make two or more? Zylicz, Zbigniew; Mercadante, Sebastiano // Advances in Palliative Medicine;2010, Vol. 9 Issue 2, p31 

    Despite a more than tenfold increase in opioid consumption in the past decades, many cancer patients still suffer pain. The current understanding of this situation is poorly understood. It is still possible that in some countries pain is still undertreated, but it is also possible that we do not...

  • Evolving Cancer Pain Treatments: Rational Approaches to Improve the Quality of Life for Cancer Patients. Knopp, Kelly L.; Nisenbaum, Eric S.; Arneric, Stephen P. // Current Pharmaceutical Biotechnology;Oct2011, Vol. 12 Issue 10, p1627 

    Most cancer patients will experience moderate to severe pain and/or neuropathy during the course of their disease. Recent improvements in the primary treatment of cancer have increased the life span of cancer patients, but not necessarily their quality of life (QoL). The pain and suffering...

  • 'Safe and Effective When Used As Directed': The Case of Chronic Use of Opioid Analgesics. Ballantyne, Jane // Journal of Medical Toxicology;Dec2012, Vol. 8 Issue 4, p417 

    Opioid analgesics have been used increasingly over the past 20 years for the management of chronic non-cancer pain in the USA under the assumption that they were safe and effective when used as directed. The accuracy of that assumption has not been tested against accumulated evidence. The safety...

  • Opioid-taking self-efficacy affects the quality of life of Taiwanese patients with cancer pain. Liang, Shu-Yuan; Ding, She-Anne; Wu, Wei-Wen; Liu, Chieh-Yu; Lin, Chia-Chin // Supportive Care in Cancer;Jul2015, Vol. 23 Issue 7, p2113 

    Goals: Quality of life is an important indicator for evaluating the outcome of treatment for patients with cancer pain. Perceived self-efficacy has been reported to play an important role in controlling quality of life (QOL). Limited studies have focused on opioid-taking self-efficacy effects on...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics